A summary of the dogs used to detect sleep disturbances with PLUS CYCLE^®. by Akihiro Ohnishi (10989900)

Subjects:

Maps of median projected λ_<i>S</i> (a) and <i>R</i>₀ (b) across 1st-level sub-national administrative regions in selected South American countries. by Keith Fraser (1868587)

Subjects:

List of primers used in this study. by Haotian Ma (11100492)

Subjects:

Graph of the risk of bias for the included randomized controlled trials (A); Summary of the risk of bias for the included randomized controlled trials (B). by Zhuoyang Xia (21354186)

Subjects:

The interaction effect of urinary bisphenol A exposure levels at two time points during childhood on serum thyroid hormone concentrations in adolescence. by Jung Eun Choi (563339)

Subjects:

Eggs jointly coordinate a caspase-1 and caspase-8 dependent pyroptotic cell death. by Madhusoodhanan Suresh Kumar Meena Kumari (20896666)

Subjects:

Effect of ex vivo treatment with rhTGFβ1 or a TGFβ1 inhibitor on monocyte responses to rgE stimulation. Monocytes and NK cells purified from PBMC collected from 10 RZV recipients (demographics in S4 Table) before vaccination (D0) and 90 days post-vaccination (D90) were combined ex vivo and stimulated with VZV-rgE. A subset of D0 monocyte & NK cocultures was also treated with the TGFβ1 inhibitor LY (D0 LY), and a subset of D90 cocultures were supplemented with rhTGFβ1. The graph shows individual data points, means and p values calculated by Friedman test for repeated measures with FDR correction. LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90. Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0. by Michael J. Johnson (5818168)

“…Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0.…”

<i>In vitro</i> characterization of the mnuA::Tn and 0690::Tn mutants. by Aga E. Gelgie (17661720)

Subjects:

Supplementary Material for: Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (... by figshare admin karger (2628495)

“…Conclusion: Adj AVD at these doses enabled 35% more iPTH reduction in ND-CKD patients with mild to moderate SHPT on long-term ERC treatment but increased mean serum Ca and P by 0.40 and 0.27 mg/dL, respectively, FGF23 by more than 2-fold and eGFR decline by 4-fold, suggesting that adding AVD to ERC has untoward effects that override the nephrosparing impact of iPTH reductions with ERC treatment alone. …”

DDC for four anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Isotype control overlays. by Chen Lu (135200)

Subjects:

Original uncropped blot. by Chen Lu (135200)

Subjects:

Raw Data. by Chen Lu (135200)

Subjects:

Identification of BM-MSCs. by Chen Lu (135200)

Subjects: